NABRIVA THERAPEUTICS US, INC. – Trademark Portfolio
Entity Type: 03
NABRIVA THERAPEUTICS US, INC. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 4 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include XENLETA and NABRIVA THERAPEUTICS. The owner is based in KING OF PRUSSIA, PA.
1000 CONTINENTAL DRIVE
SUITE 600
KING OF PRUSSIA, PA 19406
Showing of trademarks Trademarks
Trademark Classifications
NABRIVA THERAPEUTICS US, INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does NABRIVA THERAPEUTICS US, INC. have?
NABRIVA THERAPEUTICS US, INC. has 4 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 abandoned.
What trademark classes does NABRIVA THERAPEUTICS US, INC. file in?
NABRIVA THERAPEUTICS US, INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are NABRIVA THERAPEUTICS US, INC.'s most well-known trademarks?
NABRIVA THERAPEUTICS US, INC.'s registered trademark portfolio includes well-known marks such as XENLETA and NABRIVA THERAPEUTICS. These are among 3 currently registered trademarks in the portfolio.
What is NABRIVA THERAPEUTICS US, INC.'s trademark registration success rate?
NABRIVA THERAPEUTICS US, INC. has a 75% trademark registration rate, with 3 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.